Immunogenicity of Abdala COVID-19 vaccine in Vietnamese people after primary and booster vaccinations: A prospective observational study in Vietnam

Thanh, Tran Tan; Tu, Nguyen Thi Kha; Nguyet, Lam Anh; Thuy, Cao Thu; Thuan, Nguyen Lam Thai; Ny, Nguyen Thi Han; Nhu, Le Nguyen Truc; Thanh, Le Kim; Hong, Nguyen Thi Thu; Anh, Nguyen To; Truong, Nguyen Thanh; Chau, Nguyen Van Vinh; Yen, Lam Minh; Van E, Phan; Thuong, Nguyen Phong; Van Truc, Nguyen; Trung, Pham Huu; Yap, Wee Chee; Pandey, Rahul; Yee, Sidney; Weng, Ruifen; Mongkolsapaya, Juthathip; Dejnirattisai, Wanwisa; Hamers, Raph L; Chantratita, Narisara; Screaton, Gavin; Dunachie, Susanna J; Jones, E Yvonne; Stuart, David I; Dung, Nguyen Thanh; Thwaites, Guy; Wang, Lin-Fa; Tan, Chee Wah; Tan, Le Van

doi:10.1016/j.ijid.2024.107173

International Journal of Infectious Diseases

2024

DOI: 10.1016/j.ijid.2024.107173

|View full text |Cite

Immunogenicity of Abdala COVID-19 vaccine in Vietnamese people after primary and booster vaccinations: A prospective observational study in Vietnam

Tran Tan Thanh,

Nguyen Thi Kha Tu,

Lam Anh Nguyet

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Preprint1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Structural and Functional Glycosylation of the Abdala COVID-19 Vaccine

Burnap,

Calvaresi,

Cabrera

et al. 2024

Preprint

View full text Add to dashboard Cite

Abdala is a COVID-19 vaccine produced in Pichia pastoris and is based on the receptor-binding domain (RBD) of the SARS-CoV-2 spike. Abdala is currently approved for use in multiple countries with clinical trials confirming its safety and efficacy in preventing severe illness and death. Although P. pastoris is used as an expression system for protein-based vaccines, yeast glycosylation remains largely uncharacterised across immunogens. Here, we characterise N-glycan structures and their site of attachment on Abdala and show how yeast-specific glycosylation decreases binding to the ACE2 receptor and a receptor-binding motif (RBM) targeting antibody compared to the equivalent mammalian-derived RBD. Reduced receptor and antibody binding is attributed to changes in conformational dynamics resulting from N-glycosylation. These data highlight the critical importance of glycosylation in vaccine design and demonstrate how individual glycans can influence host interactions and immune recognition via protein structural dynamics.

show abstract

Structural and Functional Glycosylation of the Abdala COVID-19 Vaccine

Burnap,

Calvaresi,

Cabrera

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Immunogenicity of Abdala COVID-19 vaccine in Vietnamese people after primary and booster vaccinations: A prospective observational study in Vietnam

Cited by 1 publication

References 18 publications

Structural and Functional Glycosylation of the Abdala COVID-19 Vaccine

Structural and Functional Glycosylation of the Abdala COVID-19 Vaccine

Contact Info

Product

Resources

About